The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective cohort study on the risk factors of admission due to serious adverse events during S-1 (tegaful, gimeracil, oteracil potassium) containing chemotherapy for gastric cancer.
Yasuyuki Kawamoto
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Yoshimitsu Kobayashi
No relevant relationships to disclose
Koji Oba
No relevant relationships to disclose
Hideyuki Hayashi
No relevant relationships to disclose
Hiroshi Nakatsumi
No relevant relationships to disclose
Yoshito Komatsu
No relevant relationships to disclose